Crucell Awarded an additional Quinvaxem(TM) Vaccine contract of over $20 Million for 2007
This contract is valid for 2007 and in addition to the contract which has been awarded to Crucell December 1 by supranational organizations totaling over US$ 230 million for both its Quinvaxem(TM) and Hepavax-Gene® pediatric vaccines representing minimum sales to these supranational organizations over the next three years including 2009. Following the WHO pre-qualification in September 2006, the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.
Quinvaxem(TM), a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell's laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.